Author:
Balbach Lisa,Wallaschofski Henri,Völzke Henry,Nauck Matthias,Dörr Marcus,Haring Robin
Abstract
Abstract
Background
To investigate potential associations of serum prolactin concentration (PRL) with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM), previously observed in small and selected study samples, in a large population-based cohort.
Methods
Data from 3,993 individuals (2,027 women) aged 20-79 years from the population-based Study of Health of Pomerania (SHIP) were used to analyse cross-sectional and longitudinal associations of PRL with MetS and T2DM risk in age- and multivariable-adjusted Poisson regression models. PRL were log-transformed and modelled as continuous (per standard deviation (SD) increase) and categorical predictor (sex-specific quartiles) variable, separately for men and woman.
Results
Cross-sectional analyses showed an inverse association between low PRL concentrations and prevalent T2DM risk in men and women after multivariable-adjustment (men: Q1 vs. Q4: relative risk (RR), 1.55; 95% confidence interval (CI), 1.13 – 2.14; women: Q1 vs. Q4: RR, 1.70; 95% CI, 1.10 – 2.62). Likewise, higher PRL concentrations were associated with significantly lower T2DM risk (RR per SD increase in log-PRL: 0.83; 95% CI, 0.72 – 0.95 in men, and 0.84; 95% CI, 0.71 – 0.98 in women, respectively). An inverse association between PRL and MetS risk was not retained after multivariable adjustment. Longitudinal analyses yielded no association of PRL with incident MetS or T2DM.
Conclusion
The present study is the first large population-based study reporting a cross-sectional inverse association between PRL and prevalent T2DM in both genders. But the absent longitudinal associations do not support a causal role of PRL as a risk factor of incident MetS or T2DM.
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Endocrinology, Diabetes and Metabolism
Reference46 articles.
1. Cejkova P, Fojtikova M, Cerna M: Immunomodulatory role of prolactin in diabetes development. Autoimmun Rev. 2009, 9 (1): 23-27. 10.1016/j.autrev.2009.02.031.
2. Brandebourg T, Hugo E, Ben-Jonathan N: Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab. 2007, 9 (4): 464-476. 10.1111/j.1463-1326.2006.00671.x.
3. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR: Focus on prolactin as a metabolic hormone. Trends in endocrinology and metabolism. TEM. 2006, 17 (3): 110-116.
4. Prasad H, Ryan DA, Celzo MF, Stapleton D: Metabolic syndrome: definition and therapeutic implications. Postgrad Med. 2012, 124 (1): 21-30. 10.3810/pgm.2012.01.2514.
5. Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, Kawamori R: Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol. 2008, 93 (10): 3671-3689. 10.1210/jc.2008-0222.
Cited by
79 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献